Meropenem Sun (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final stage of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial cell death. Its structure resists most beta‑lactamases, providing activity against a wide range of resistant pathogens.

The dose of Meropenem Sun is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Dosing regimens may range from 0.5 g to 2 g administered intravenously every 8 hours, but the exact schedule must be determined by a qualified healthcare professional.

Safety data for Meropenem during pregnancy and lactation are limited. The drug should be used only when the potential therapeutic benefit justifies any possible risk to the fetus or infant. Clinicians should assess the risk‑benefit ratio carefully and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Meropenem Sun product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Meropenem offers a broad spectrum of activity, including stability against many beta‑lactamases, making it effective against multidrug‑resistant Gram‑negative and Gram‑positive bacteria. Compared with other carbapenems such as imipenem or ertapenem, meropenem has a slightly broader anaerobic coverage and a lower propensity for seizures, though all carbapenems share similar mechanisms and resistance concerns.

Meropenem Sun must be stored refrigerated at 2 °C to 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature for a short period during preparation, it should be used promptly and not re‑refrigerated.

Meropenem Sun is supplied as a sterile injectable solution for intravenous infusion. The vial is reconstituted with the appropriate diluent, then administered over 15–30 minutes, depending on the clinical protocol. Administration must be performed by qualified healthcare personnel in a setting that ensures aseptic technique.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders; severe allergic reactions such as anaphylaxis; Clostridioides difficile‑associated colitis; significant renal toxicity; and rare cases of hepatic failure. Prompt recognition and discontinuation of therapy are essential if any of these events occur.

Meropenem Sun is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with severe renal impairment who have not had dose adjustments, and for patients with a history of seizures unless the benefits outweigh the risks.